IN8BIO, INC. (INAB) - Q1 2025 Filing Summary
Business Context and Reporting Period
Company: IN8BIO, INC.
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: IN8bio is a clinical-stage biopharmaceutical company focused on gamma-delta T cell product candidates for solid and liquid tumors. The company's lead candidate, INB-100, is in an investigator-sponsored Phase 1 trial for acute myeloid leukemia (AML). In September 2024, the company announced a pipeline prioritization strategy, suspending the INB-400 Phase 2 trial and reducing its workforce by approximately 49% to optimize resource allocation.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(5,550) | $(8,562) |
| Net Loss Per Share (Basic & Diluted) | $(0.07) | $(0.20) |
| Total Operating Expenses | $5,660 | $8,645 |
| Research & Development Expenses | $2,972 | $4,903 |
| General & Administrative Expenses | $2,688 | $3,742 |
| Cash and Restricted Cash (End of Period) | $12,157 | $13,271 |
| Net Cash Used in Operating Activities | $(3,122) | $(7,919) |
| Net Cash Provided by Financing Activities | $3,893 | $(277) |
| Accumulated Deficit | $(127,206) | $(99,781) |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by $2.99 million (35%) compared to Q1 2024. This was driven by a $1.93 million decrease in R&D expenses and a $1.05 million decrease in G&A expenses, primarily due to the September 2024 workforce reduction and associated cost-saving measures.
- Improved Loss Profile: Net loss narrowed by $3.01 million year-over-year, reflecting the successful implementation of cash preservation strategies.
- Capital Raising: The company generated $3.89 million in net cash from financing activities in Q1 2025, primarily from the sale of 7.36 million shares under its At-The-Market (ATM) program ($3.7 million) and the exercise of Series C warrants ($0.4 million). In contrast, Q1 2024 saw a net cash outflow from financing.
- Share Count: Weighted-average shares outstanding increased significantly from 43.3 million in Q1 2024 to 83.5 million in Q1 2025 due to equity issuances.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern. As of March 31, 2025, cash of $11.9 million is not anticipated to fund operations for at least 12 months. Management plans to raise additional capital through equity/debt offerings or strategic collaborations.
- Pipeline Strategy: The company is focusing on advancing INB-100 (AML) and seeking partnerships for INB-400 (Glioblastoma), which remains suspended. New preclinical data for the INB-600 T cell engager platform was presented in April 2025.
- Subsequent Events (April 2025):
- Received $1.9 million in net proceeds from the exercise and exchange of Series A and Series B warrants.
- Amended Series B warrants to reduce the exercise price from $1.50 to $0.45 per share.
- Terminated an operating lease for unutilized office space in Birmingham, Alabama, incurring a $0.1 million termination fee.
- Risk Factors: Key risks include the inability to raise additional capital, potential delisting from Nasdaq due to minimum bid price non-compliance (currently in a compliance period until August 2025), and the high uncertainty of clinical trial outcomes for novel cell therapies.
Investor Verification Checklist
- Liquidity Runway: Verify the company's ability to secure funding before cash reserves are depleted (projected into March 2026 based on current burn rate).
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive days before the August 4, 2025 compliance deadline to avoid delisting.
- Dilution Impact: Assess the impact of outstanding warrants (Series A, B, and C) and the recent ATM sales on future shareholder dilution.
- Clinical Milestones: Track the enrollment and data readout timelines for the INB-100 expansion cohort, which is critical for future funding and partnership discussions.
- Cost Structure: Confirm that the 49% workforce reduction has stabilized operating expenses and that no further significant cost-cutting measures are required.